We also found that the addition of a YAP1 inhibitor to immunotherapy further enhanced anti-tumor activity and remodeled TME (Fig. 7), indicating the great potential of combining YAP1 and PD-L1 blockade in the clinical treatment of the SCLC-Y subtype, an approach that is expected to improve the prognosis of SCLC patients. This evidence concerns the gene YAP1 and neoplasm.